<DOC>
	<DOCNO>NCT00297336</DOCNO>
	<brief_summary>A 6-month , observational , post authorization safety study collection evaluation additional safety data topiramate prophylactic treatment migraine adult patient . According current European international guideline safety efficacy drug continuously monitor even approval market circulation.The applicable method monitor include : Observational study , voluntarily report adverse event , clinical trial IV phase Post Authorization Safety Studies ( PASS ) . Post Authorization Safety Studies ( PASS ) use product significant source information regard action drug therapeutic method circumstance every day clinical practice .</brief_summary>
	<brief_title>An Observational Study Evaluating Safety Topiramate Prevention Migraine</brief_title>
	<detailed_description>Previous study show topiramate effective prevent migraine headache . This 6-month observational study evaluate additional safety data topiramate prevention migraine adult patient . The study duration 6-months , 5 study visit study . Administration topiramate accord current Summary Product Characteristics ( SmPC ) daily clinical practice . The decision prescribe topiramate decide Health Care Professional independent protocol . Based investigator 's judgement , patient enter study fulfill criterion administration prophylactic treatment . In study total number 80 patient diagnosed migraine accord criterion International Headache Society HIS ( Cephalalgia 1998 ; 8 ( Suppl7 ) :1-98 ) participate . Patients enrol either male female 18 year age , fulfil mention criterion agree sign write informed consent anonymous confidential use medical data participation study . Methods evaluation include tolerability , laboratory test , vital sign Body Weight Body Mass Index ( BMI ) . Efficacy assess migraine attack , symptomatic medication Headache Impact Test ( HIT-6 ) . Observational study - No investigational drug administer .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Patients meet IHS ( International Headache Society ) diagnostic criterion migraine Patients satisfy migraine prophylactic medication criterion Ineligible patient accord market Summary Product Characteristics topiramate Patient hypersensitivity topiramate component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Topiramate</keyword>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
	<keyword>Chronic headache</keyword>
	<keyword>Chronic migraine</keyword>
</DOC>